Novo Nordisk Shares Face Mounting Pressure as Setbacks Pile Up

Danish pharmaceutical giant Novo Nordisk finds itself navigating turbulent waters following a series of damaging developments. Investors are growing increasingly concerned as the maker of blockbuster drugs Ozempic and Wegovy confronts multiple challenges simultaneously, raising questions about the sustainability of its previous growth trajectory.

Strategic Partnership Collapses as Valuation Faces Downgrade

Thursday delivered a dual blow to the company’s prospects. First, research firm Morningstar substantially reduced its fair value estimate for Novo Nordisk shares, citing intensifying pricing pressures within the U.S. obesity medication market. The firm indicated that recent pricing agreements with the U.S. government would likely impact the company’s financial performance sooner than previously anticipated.

Simultaneously, biotechnology company Korro Bio announced that Novo Nordisk had suspended their collaborative research efforts. This decision followed disappointing clinical trial results for Korro’s lead drug candidate, KRRO-110. The termination not only forced Korro into a strategic repositioning but also resulted in workforce reductions affecting 34% of its employees.

Competitive Landscape Intensifies

These recent setbacks form part of a concerning pattern for the pharmaceutical leader. Just days earlier, Novo Nordisk suffered a significant defeat in the high-stakes bidding competition for U.S. developer Metsera, losing out to rival Pfizer. This represents a substantial strategic loss in the battle for promising pipeline assets within the rapidly expanding obesity treatment sector.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The pricing concessions made to the U.S. government, initially intended to improve patient access to Wegovy and Ozempic, are already revealing negative consequences. Company projections now indicate a slight revenue decline anticipated for 2026 as a direct result of these agreements.

Path Forward Under Scrutiny

Market attention now turns to tomorrow’s extraordinary general meeting, where investors await clear signals regarding the company’s strategic direction. The election of new supervisory board members could prove instrumental in setting the course for the embattled pharmaceutical firm’s recovery.

Despite these consecutive challenges, numerous market analysts maintain either “Buy” or “Hold” recommendations on the stock. The next critical test arrives on February 4, 2026, when Novo Nordisk discloses its full-year 2025 financial results. Until then, investor patience is likely to be tested as the company works to regain its footing in an increasingly competitive marketplace.